600062 Stock Overview
China Resources Double-Crane Pharmaceutical Co.,Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
China Resources Double-Crane Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥19.73 |
| 52 Week High | CN¥26.15 |
| 52 Week Low | CN¥15.94 |
| Beta | 0.16 |
| 1 Month Change | -5.64% |
| 3 Month Change | -8.23% |
| 1 Year Change | 6.65% |
| 3 Year Change | 52.00% |
| 5 Year Change | 51.19% |
| Change since IPO | 593.08% |
Recent News & Updates
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 29
China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement
Oct 21An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued
Sep 30Recent updates
The China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 29China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Low P/E No Reason For Excitement
Oct 21An Intrinsic Calculation For China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Suggests It's 49% Undervalued
Sep 30We Think China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) Can Manage Its Debt With Ease
Jul 16China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 24Investors Don't See Light At End Of China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Tunnel
Mar 02Shareholder Returns
| 600062 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.6% | -1.0% | 0.4% |
| 1Y | 6.6% | -3.0% | 12.3% |
Return vs Industry: 600062 exceeded the CN Pharmaceuticals industry which returned -3% over the past year.
Return vs Market: 600062 underperformed the CN Market which returned 12.3% over the past year.
Price Volatility
| 600062 volatility | |
|---|---|
| 600062 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 600062 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600062's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 12,269 | Wenchao Lu | www.dcpc.com |
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, and other.
China Resources Double-Crane Pharmaceutical Co.,Ltd. Fundamentals Summary
| 600062 fundamental statistics | |
|---|---|
| Market cap | CN¥20.50b |
| Earnings (TTM) | CN¥1.35b |
| Revenue (TTM) | CN¥10.32b |
15.0x
P/E Ratio2.0x
P/S RatioIs 600062 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600062 income statement (TTM) | |
|---|---|
| Revenue | CN¥10.32b |
| Cost of Revenue | CN¥4.54b |
| Gross Profit | CN¥5.79b |
| Other Expenses | CN¥4.44b |
| Earnings | CN¥1.35b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.31 |
| Gross Margin | 56.06% |
| Net Profit Margin | 13.06% |
| Debt/Equity Ratio | 6.3% |
How did 600062 perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield27%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 10:04 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Resources Double-Crane Pharmaceutical Co.,Ltd. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhi Xue Diao | Avic Securities Co., Ltd |
| Jessica Li | BofA Global Research |
| Helena Qiu | CCB International Securities Limited |